Sluggish Copaxone Rival And Delay To Generic Advair Hurt Mylan
Mylan has blamed a sluggish uptake for its Copaxone rival and a delay in FDA approval of its generic version of Advair Diskus for the firm’s sales suffering a 4% drop and EBITDA falling by 8% in 2018.
You may also be interested in...
Viatris’ Mylan has accused Teva of creating a perfect ‘playbook’ to delay Mylan’s launch of a generic version of its Copaxone blockbuster and then strangle uptake, something Mylan was vocal about years earlier, in a suit filed in a New Jersey court.
Revance has amended its agreement with Mylan to collaborate on a rival version of Botox to give Mylan more time to decide on whether it wants to continue developing the biosimilar. In turn, Mylan has agreed to pay $5m to Revance for the extended deadline.
Pfizer has announced plans to merge its off-patent unit with Mylan, creating a new generics and biosimilars giant in the US.